Old and new issues in cervical cancer control.

Authors:
  • CCCathy W. Critchlow
    Cathy W. Critchlow
  • NKNancy B. Kiviat
    Nancy B. Kiviat

Abstract
Clearly, one of the public health successes of the last 50 years has been the development of an effective approach to cervical cancer control. Dramatic decreases in the incidence of invasive cervical cancer (ICC) have occurred following the establishment of routine cytologic screening and treatment of those lesions (severe dysplasia or carcinoma in situ [CIS]) thought to be immediate precursors of ICC. Although it is widely agreed that the aim of cervical cytologic screening should be the identification of all women with these high-grade lesions, there is little agreement as to how best to achieve this. Until recently, in many countries such as Canada, physicians primarily relied on cytology alone to identify women with severe dysplasia/CIS, with referral for colposcopy largely reserved for confirmation of the cytologic diagnosis. However, in the United States, the majority of women with a cytologic diagnosis of mild dysplasia, moderate dysplasia, and repeated squamous atypia (or atypical squamous cells of uncertain significance [ASCUS]) have also been referred for colposcopy and biopsy. The rationale for this approach has been the belief that ASCUS and cervical intraepithelial neoplasia (CIN) grades 1, 2, and 3/CIS represent successive, progressive stages in the pathogenesis of cervical cancer. Furthermore, referral of women with ASCUS or CIN-1 has also been based on the fear that cytologic screening might miss more serious lesions, especially small CIN-3 lesions located high in the endocervical canal.

This publication has 7 references indexed in Scilit: